The first synthesis of 3-deoxyoripavine and its utilization in the preparation of 10-deoxyaporphines and cyprodime by Sipos, Attila et al.
1 
 
The first synthesis of 3-deoxyoripavine and its utilization in the preparation of 10-
deoxyaporphines and cyprodime 
 
Attila Sipos,
1*
 Antal Udvardy,
2
 Attila C. Bényei
1,2 
and Sándor Berényi
3
 
 
1
Department of Pharmaceutical Chemistry, Medical and Health Science Centre, University of 
Debrecen, P.O. Box 70, H-4010 Debrecen, Hungary 
2
Department of Physical Chemistry, University of Debrecen, P.O. Box 7, H-4010 Debrecen, 
Hungary 
3
Department of Organic Chemistry, University of Debrecen, P.O. Box 20, H-4010 Debrecen, 
Hungary 
 
This paper is dedicated to the memory of Prof. Sándor Makleit who passed away on 
27.09.2012 
 
Abstract - The synthesis of 3-deoxyoripavine (7) was realized as a novel and promising 
intermediate towards the synthesis of the important class of dopaminergic and/or serotonergic 
10-deoxyaporphines and the special pharmacological tool µ opioid antagonist cyprodime. 
Generally, the preparation of these valuable biologically active compounds was achieved in 
remarkable yields. 
_________________________________________________________________________________________________________________ 
 
The synthesis and neuropharmacological characterization of 10-deoxyapomorphine 
derivatives are a new and important direction in the development of potent and subtype 
selective dopaminergic and/or serotonergic ligands [1-6]. Currently all the synthetic methods 
towards deoxyapomorphines are based on the preparation of 3-O-(trifluoromethyl)sulfonyl-
morphine (2) or -oripavine (5), the acid-catalyzed rearrangement of these morphinans into 
aporphinoids and further manipulations on the sensitive aporphine backbone. Earlier 
procedures involved the synthesis and transformation of 3-(1-phenyltetrazoyl)morphine (3) 
[7, 8], however the rearrangement of this compound gave rise to a mixture of aporphines and 
the hydrogenolytic removal of the (phenyltetrazolyl)oxy moiety from the aporphines was 
reported to be ’erratic and capricious’ in both catalytic hydrogenolysis reactions and in 
catalytic hydrogen-transfer reactions [8, 9].  
 
Figure 1. Structure of morphinans currently used for the synthesis of 10-deoxyapomorphines 
 
Here we report a new, efficient and versatile route to 10-deoxyaporphines based on hitherto 
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unknown 3-deoxyoripavine (7). The practical significance of this procedure is even higher 
due to the fact that the starting derivative of our procedure, oripavine (4), is one of the major 
industrial poppy alkaloids [10-12].      
Towards the synthesis of 3-deoxyoripavine (7) we identified in view of literature two 
potential starting materials; either the 3-O-(trifluoromethyl)sulfonyl- 5 or 3-O-(1-
phenyltetrazoyl)-derivatives 6 of the parent alkaloid 4. The challenge in the preparation of the 
3-deoxy derivative was to find an appropriate hydrogenolytic procedure active enough to 
remove the 3-etheral moiety but keep unaffected the conjugated diene system of ring C 
known to be especially sensitive to reductive and acidic conditions [11]. The phenyltetrazoyl 
ether 6 was prepared in excellent yields (94%) from oripavine (4) according to the protocol 
used for the synthesis of the similar morphine ether [7]. The procedure, in which the free base 
of 4 and 5-chloro-1-phenyl-1H-tetrazole was refluxed in acetone in the presence of K2CO3, 
resulted white crystals allowing us to perform X-ray analysis (Fig. 2, CCDC 860893) of the 3-
etheral region of the molecule in view of a previous study [13]. The C3-O bond length is 
1.413Ǻ, and the C3-O-C bond angle was 116.6o which are close the average values 
determined by Johnstone et al. [13] for a series of tetrazoyl ethers used for the removal of 
phenolic OH function.  
 
 
Figure 2. X-ray structure of compound 6, showing 50% probability displacement ellipsoids 
(H atoms omitted for clarity) 
 
This study confirmed that compound 6 is a promising starting derivative for the synthesis of 
3-deoxyoripavine (7) on the basis of the determining parameters deduced of Johnstone’s 
group [14-17]. The alternative starting compound of the aimed deoxygenated oripavine 7 was 
the 3-O-[(trifluoromethyl)sulfonyl]oripavine (5) prepared according to the literature 
procedure in 75% yield [2].   
There were several potential hydrogenolytic conditions identified in the literature, however, as 
it was referred, finding the appropriate reductive capacity and acidity of the applied 
conditions was the real task of a complex optimization procedure. This procedure is 
summarized in Table 1 focusing on the most relevant steps.  
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Table 1. Results of the hydrogenolysis reactions aiming 3-deoxyoripavine (7) 
 
Reactions Starting 
diene 
H-donor Catalyst Base Ligand Isolated 
yield (%) 
of 7 
Reference 
to the 
procedure 
1 6 NH2NH2.H2O
a 
10% Pd/C - - 5 14, 15 
2 6 NaH2PO2
b 
10% Pd/C - - 7 15 
3 6 1,4-
cyclohexadiene
c 
10% Pd/C - - 17 15 
4 5 HCOOH
d 
Pd(OAc)2 Et3N PPh3 37 18 
5 5 HCOOH
d 
Pd(OAc)2 Et3N dppf 49 18 
6 5 (MeOH)
e 
10% Pd/C 
- Mg 
- - 15 19 
7 5 HCOONH4, 
(MeOH)
e 
10% Pd/C 
- Mg 
- - 43 19 
8 5 HCOOH+Et3N
f 
Pd(OAc)2 Et3N dppf 92 20 
aTwo-phase system of toluene:ethanol:water=7:3:2, r.t., 1.5 h, under argon. b0.4M aquoeous solution of NaH2PO2, toluene:ethanol=7:3, 
reflux (ca. 70oC) under argon, 1h. cRefluxing methanol under argon, 1.5 h; d0.2 eq. Pd(OAc)2, 3 eq. Et3N, 0.4 eq. phosphine [dppf=1,1’-
bis(diphenylphosphino)-ferrocene], 2 eq. 99% HCOOH, DMF, 60oC, under argon, 1h. e1 eq. HCOONH4, 1.2 eq. Mg in carefully 
deoxygeneted abs. MeOH under argon, r.t., 2h. f2.5 eq. HCOOH, 3.8 eq. Et3N, 0.1 eq. Pd(OAc)2, 0.15 eq. dppf, DMF under argon, 60
oC, 12 
h. 
 
The hydrogenolysis of the tetrazoyl ethers is usually achieved by catalytic hydrogenation; 
however this route was ruled out as a potential method on the basis of literature reports
 
[21].  
The hydrogenolysis of morphine-3-tetrazoyl ether resulted 3-deoxydihydromorphine and it is 
well known that the reductive stability of morphine-type alkaloids is considerably higher than 
the same for oripavine-type diene structures. Therefore, several attempts were made for the 
selective transfer hydrogenation of tetrazoyl moiety with different hydrogen donors. As it can 
be concluded from Table 1, these methods gave rise to the expected compound in poor yields 
(Entries 1 &2). In case of hydrazine the crude reaction mixture contained fully and partially 
saturated morphinans without 3-OH function besides the aimed compound 7. The application 
of sodium hypophosphite led to a very complex mixture with partially saturated morphinans. 
The most promising attempts were made with 1,4-cyclohexadiene as H-donor. Besides 17% 
of target 3-deoxyoripavine (7) the mixture of partially saturated morphinans with unprotected 
3-OH functions were also obtained. Generally the procedures based on 3-O-
[(trifluoromethyl)sulfonyl]oripavine (5) proved to be a promising starting compound in view 
of the Pd-catalyzed deoxygenating methods. The application of formic acid in the presence of 
Pd(OAc)2, triethylamine and triphenylphosphine led to compound 7 in 37% yield (Entry 4), 
however the use of sterically more demanding dppf resulted higher yield (49%) probably due 
to a steric hindrance towards ring C of the skeleton. Palladium-on-charcoal with magnesium 
metal in methanol gave rise to low amount of product besides a mixture of saturated 
morphinans. It was suggested that the application of ionic additives could improve efficacy 
and required reaction time [19]. In the course of those experiments ammonium acetate was 
found to be the best; however in our hands the use of ammonium formate resulted the highest 
conversion into the desired compound. It is interesting to note that according to the plausible 
mechanism suggested by Mori et al. methanol is an indirect H-donor interacting with 
magnesium [19]. The most efficient procedure for the synthesis of targeted product 7 (92%, 
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Entry 8) was the one formic acid and an excess of triethylamine in the presence of Pd(OAc)2 
and dppf. In case of replacing dppf with PPh3 gave rise to considerably lower yields. 
In order to further investigate the performance and conformity of our best conditions with 
different electronic systems in ring C, we synthesized the corresponding triflates of morphine 
(1), γ-isomorphine (8) and neomorphine (9) according to the method described for the 
synthesis of (-)-3-O-[-(trifluoromethyl)sulfonylmorphine (2) [1]. On the basis of the 
difference in the substitution pattern and electronic structure of the ring C of γ-isomorphine 
(8) [22] and neomorphine (9) [23] these compounds considered as hydroxylated metabolites 
of morphine (1) itself [24].  The triflate formation of alkaloids 1, 8 and 9 (Scheme 1) was 
performed in excellent yields (84-91%).  
 
Scheme 1. Synthesis of 3-deoxymorphinans 
 
The previously presented methodology (Table 1, Entry 8) for the hydrogenolysis of 3-O-
triflate function was successfully applied for compounds 2, 10, 11 giving rise to the expected 
3-deoxygenated morphinans 12-14 in 85-91% yields. The formation of products with 
saturated ring C of the morphinan skeleton was not observed. Therefore it can be stated that 
the substitution pattern and the position of the double bond in ring C are not limiting factors 
of the application of the 3-deoxygenation of morphinans. 
As it was referred previously, one of the main areas for the utilization of new 3-
deoxyoripavine (7) was the acid-catalyzed rearrangement into 10-deoxyaporphines exploiting 
all the accumulated knowledge regarding this procedure [25]. 
 
Scheme 2. Synthesis of 2-substituted-11-hydroxyaporphines, the isolated yields for products 
15-20 and the literature references for known compounds  
 
The data summarized in Scheme 2 suggest that the acid-catalyzed rearrangement could be 
realized starting from deoxymorphinandiene 7 rather than from morphine (1) or oripavine (4) 
as in this new method no catechol system is involved. This catechol system often leads to the 
appearance of oxidized by-products [29]. These side-products make the work-up procedure 
difficult and contribute to the decrease of isolated yields. In these cases the average isolated 
yields of three runs were found to be good to excellent. Taking into consideration the high 
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yileding 3-O-triflation of oripavine and 3-deoxygenation of compound 5, the overall yields for 
this series of 10-deoxyaporphines 15-20 were in the range of 51-62%.  
Cyprodime [30] is a prototypical, selective µ opioid antagonist which is still the target of 
intense pharmacological research in part because of the availability of its tritium-labelled 
derivative [31]. The original synthesis of the cyprodime was based on the preparation of key 
intermediate 25 from oxymorphone, an expensive semi-synthetic major analgesic, in 6 steps 
[30, 32]. The structure of compound 7 offers the shortening of this procedure as it is presented 
in Scheme 3. 
 
Scheme 3. New route to key intermediate 25 of the synthesis of cyprodime 
 
All these standard synthetic steps were performed in accordance with a previous report on the 
alternative synthesis of cyprodime [33]. The overall yield for key intermediate 25 was 32% in 
the present 5-step study.  Interestingly, it was possible to obtain the trimethoxymorphinan 24 
in average yield (59%) under usual O-methylation conditions [31] in the presence of 5 
equivalents of NaH and (CH3)2SO4. The position of the double bond in ring C was established 
on the basis of the coupling constants of H7. 
 
Conclusion  
 
In conclusion, the preparation of 3-deoxyoripavine (7) was achieved starting from both 3-O-
(5-phenyltetrazoil)ether and the 3-O-triflate of oripavine. The optimization of the 
hydrogenolitic conditions resulted in a highly efficient procedure yielding 92% of the desired 
compound 7. The methodology was extended for morphine (1) and its isomers and found to 
be a useful route to 3-deoxymorphinans without change in the electronic system of ring C. It 
was recognized that 3-deoxyoripavine (7) was a valuable starting product towards the 
synthesis of the important class of dopaminergic and serotonerg 10-deoxyaporphines and the 
special pharmacological tool µ opioid antagonist cyprodime.  
 
Experimental 
 
Melting points were determined with a Kofler hot-stage apparatus and are uncorrected. Thin 
layer chromatography was performed on pre-coated Merck 5554 Kieselgel 60 F254 foils 
using dichloromethane:methanol = 8:2 mobile phase. The spots were visualized with 
Dragendorff’s reagent. 1H and 13C NMR spectra were recorded on a Varian Gemini 200 MHz 
spectrometer; chemical shifts are reported in parts per million (δ) from internal TMS and 
coupling constants (J) are measured in hertz. Mass spectral measurements were performed 
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with a Bruker micrOTOF-Q instrument in the ESI mode. Elemental analyses (C, H) were 
obtained on a Carlo Erba EA1108 analyzer. 
 
Procedure for the formation of 3-O-[(trifluoromethyl)sulfonyl]morphinans 
A suspension of the alkaloid (9.20 mmol) and Et3N (1.92 mL, 13.8 mmol) in CH2Cl2 (150 
mL) kept under nitrogen was stirred for 1 h at room temperature. N-Phenyl-
trifluoromethanesulfonimide (3.94 g, 11.0 mmol) was added, and after being stirred for 48 h, 
the reaction mixture was extracted with 10% aqueous NaHCO3. The organic layer was dried 
(K2CO3), filtered, and concentrated in vacuo. The oily residue was subjected to column 
chromatography.   
 
3-O-[(Trifluoromethyl)sulfonyl]morhpine (2)  
Physical and spectral data were fully in agreement with previously published data [1].  
 
3-O-[(Trifluoromethyl)sulfonyl]oripavine (5)  
Physical and spectral data were fully in agreement with previously published data [2].  
 
γ-Isomorphine (8) 
Physical data were fully in agreement with previously published data [22].  
Calculated for free base C17H19NO3: C, 71.56; H, 6.61;  found: C, 71.49; H, 6.71; MS (ESI) 
m/z 285.1 (M+H
+
), calculated for C17H20NO3
+
: 285.2; 
1
H-NMR (DMSO-d6) δ=9.33 (s, 1H, 
OH), 6.62 (dd, 2H, H1, H2, J1-2=8.1), 5.88 (dd, 1H, H7, J7-6, 7-8α =10.9, 1.8), 5.63 (dd, 1H, H6, 
J6-7, 6-5α =10.9, 2.1), 5.09 (d, 1H, H5β,  J5β-6=2.4), 4.09 (m, 1H, H8α), 3.12 (dd, 1H, H10α, J10α-
10β, 10α-9=18.1, <2), 2.65-2.19 (m, 7H, H10β, H9, H16α, H16β, NCH3), 1.98 (m, 2H, H15β, 
H14), 1.84 (ddd, 1H, H15α, J =5.2, <2, <2). 13C-NMR (DMSO-d6) δ=144.4, 140.1, 138.3, 
129.4, 126.1, 125.4, 120.0, 118.2, 85.8, 63.5, 58.1, 47.5, 45.8, 45.1, 43.8, 32.8, 21.1. 
 
Neomorphine (9)  
Physical data were fully in agreement with previously published data [23].  
Calculated for free base C17H19NO3: C, 71.56; H, 6.61;  found: C, 71.51; H, 6.79; MS (ESI) 
m/z 285.2 (M+H
+
), calculated for C17H20NO3
+
: 285.2; 
1
H-NMR (DMSO-d6) δ=9.21 (s, 1H, 
phenolic OH), 6.69 (dd, 2H, H1, H2, J1-2=7.8), 5.48 (dd, 1H, H8, J7α-8, 7β-8=3.4, 2.2), 4.64 (d, 
1H, H5,  J5β-6β=5.3), 4.26 (dd, 1H, H6β, J6β-5β, 7β-5β=5.1, <2), 3.69 (m, 1H, H9), 3.19-2.82 (m, 
3H, H10α, H10β, H16α), 2.44-2.21 (m, 6H, H7α, H7β, H16β, NCH3), 1.96 (ddd, 1H, H15β, 
J=5.2, >2, >2), 1.81 (ddd, 1H, H15α, J =5.2, >2, >2). 13C-NMR (DMSO-d6) δ=146.4, 142.1, 
137.7, 131.2, 127.3, 124.7, 119.2, 113.4, 87.4, 66.8, 56.0, 49.1, 47.0, 43.4, 41.0, 35.4, 20.1.  
 
6,7-Didehydro-8β-hydroxy-17-methyl-3-O-[(trifluoromethyl)sulfonyl]-4,5-
epoxymorphinan (10) 
Yield: 87%; colourless oil; calculated for free base C18H18N5F3O5S: C, 51.80; H, 4.35;  found: 
C, 51.61; H, 4.61; MS (ESI) m/z 418.1 (M+H
+
), calculated for C18H19N5F3O5S
+
: 418.1; 
1
H-
NMR (CDCl3) δ=6.75 (d, 1H, H1, J1-2=8.1), 6.67 (d, 1H, H2, J1-2=8.1), 5.79 (dd, 1H, H7, J7-6, 
7-8α =11.4, 2.0), 5.60 (dd, 1H, H6, J6-7, 6-5α =11.4, 2.1), 5.12 (d, 1H, H5β,  J5β-6=2.2), 3.99 (m, 
1H, H8α), 3.17 (dd, 1H, H10α, J10α-10β, 10α-9=16.8, <2), 2.71-2.09 (m, 7H, H10β, H9, H16α, 
H16β, NCH3), 1.91 (m, 2H, H15β, H14), 1.80 (ddd, 1H, H15α, J =5.2, <2, <2). 
13
C-NMR 
(CDCl3) δ=145.1, 140.1, 137.1, 128.6, 127.2, 125.1, 120.7, 119.4 (q, JC-F=318 Hz), 113.5, 
84.9, 63.3, 57.6, 47.1, 46.0, 45.2, 43.8, 32.6, 21.2. 
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8,14-Didehydro-6α-hydroxy-17-methyl-3-O-[(trifluoromethyl)sulfonyl]-4,5-
epoxymorphinan (11) 
Yield: 84%. white foam; calculated for free base C18H18NO5F3S: C, 51.80; H, 4.37;  found: C, 
51.66; H, 4.47; MS (ESI) m/z 417.1 (M+H
+
), calculated for C18H19NO5F3S
 +
: 417.1; 
1
H-NMR 
(CDCl3) δ=7.01 (d, 1H, H2, J1-2=7.9), 6.88 (d, 1H, H1, J1-2=7.9), 5.43 (dd, 1H, H8, J7α-8, 7β-
8=3.5, 2.0), 4.67 (d, 1H, H5,  J5β-6β=5.1), 4.26 (dd, 1H, H6β, J6β-5β, 7β-5β=5.1, <2), 3.55 (m, 1H, 
H9), 3.13-2.80 (m, 3H, H10α, H10β, H16α), 2.51-2.17 (m, 6H, H7α, H7β, H16β, NCH3), 1.92 
(ddd, 1H, H15β, J=5.1, >2, >2), 1.80 (ddd, 1H, H15α, J =5.1, >2, >2). 13C-NMR (CDCl3) 
δ=147.2, 139.9, 137.7, 131.7, 127.3, 120.7, 119.7 (q, JC-F=321 Hz), 114.2, 113.6, 88.0, 66.7, 
58.1, 49.1, 46.5, 43.7, 41.0, 35.1, 23.1.  
 
Procedure for the formation of 3-(O-1-phenyltetrazol-5-yl)morphinans 
A suspension of the alkaloid (35.1 mmol) in 500 mL of acetone was allowed to reflux with 5-
chlor-l-phenyl-1H-tetrazole (6 .33 g, 35.1 mmol) and K2CO3 (10.53 g, 76.3 mmol) for 24 h. 
The reaction mixture was cooled, diluted with H2O (500 mL), and extracted with CH2Cl2. The 
extract was washed with H2O, dried over MgSO4, and filtered. The filtrate, on evaporation to 
dryness and trituration with ether, gave the 3-O-protected alkaloid. 
 
3-(O-1-Phenyltetrazol-5-yl)morphine (3) 
Physical and spectral data were fully in agreement with previously published data [1].  
 
3-(O-1-Phenyltetrazol-5-yl)oripavine (6) 
Yield: 92%; white crystals; Mp.: 183-185
o
C, calculated for free base C25H23N5O3: C, 68.01; 
H, 5.25;  found: C, 68.10; H, 5.27; MS (ESI) m/z 442.2 (M+H
+
), calculated for C25H24N5O3
+
: 
442.2; 
1
H-NMR (CDCl3) δ=7.67-7.42 (m, 5H, Ph), 6.62 (dd, 2H, H1-H2, J1-2=8.2), 5.61 (d, 
1H, H8, J7-8=6.1), 5.40 (s, 1H, H5), 5.10 (d, 1H, H7,  J7-8=6.1), 3.67 (m, 1H, H9), 3.62 (s, 3H, 
OCH3), 3.34 (1H, d, H10α,  J10α-10β= 16.4), 2.84-2.52 (m, 3H, H10β, H16α, H16β), 2,47 (s, 
3H, NCH3), 2.23 (ddd, 1H, H15β, J=5.2, >2, >2), 1.76 (ddd, 1H, H15α J=5.2, >2, >2). 
13
C-
NMR (CDCl3) δ=160.4, 154.7. 154.0, 152.4, 132.7, 131.2, 130.0, 128.7, 128.4, 127.8, 124.7, 
123.4, 120.8, 119.2, 112.5, 96.4, 91.0, 69.8, 56.5, 48.1, 46.8, 42.4, 37.2, 29.1. 
 
Optimized procedure for the hydrogenolysis of 3-O-[(trifluoromethyl)-
sulfonyl]morphinans 
1,1’-Bis(diphenylphosphino)-ferrocene (399 mg, 0.72 mmol) and palladium acetate (114 mg, 
0.48 mmol) were added to a stirred mixture of the 3-O-[(trifluoromethyl)sulfonyl]morphinan 
(4.80 mmol), triethylamine (2.56 mL, 18.24 mmol), and formic acid (0.48 mL, 12.00 mmol) 
in DMF (8 mL) at 60 
o
C under argon for 12 h. After cooling to room temperature, the reaction 
mixture was poured onto 100 mL of water. After extraction with CH2Cl2 (4 x 15 mL), the 
combined organic layers were washed with water (3 x 25 mL), dried (sodium sulfate), filtered, 
and evaporated. Treatment with boiling ethanol provided the 3-deoxymorphinan.  
 
3-Deoxyoripavine (7) 
Yield: 92%; white powder; Mp.: 136-138
o
C; calculated for free base C18H19NO2: C, 76.84; H, 
6.81;  found: C, 76.88; H, 6.88; MS (ESI) m/z 282.2 (M+H
+
), calculated for C18H20NO2
+
: 
282.1; 
1
H-NMR (CDCl3) δ=7.06 (t, 1H, H2, J1-2=7.3, J2-3=7.3), 7.06 (t, 2H, H1, H3, J1-2=7.3, 
J2-3=7.3), 5.60 (d, 1H, H8, J7-8=6.4), 5.60 (s, 1H, H5), 5.05 (d, 1H, H7,  J7-8=6.4), 3.68 (m, 
1H, H9), 3.64 (s, 3H, OCH3), 3.38 (1H, d, H10α,  J10α-10β= 16.1) , 2.97-2.62 (m, 3H, H10β, 
H16α, H16β), 2.52 (s, 3H, NCH3), 2.24 (ddd, 1H, H15β, J=5.2, >2, >2), 1.78 (ddd, 1H, H15α 
J=5.2, >2, >2). 
13
C-NMR (CDCl3) δ=157.7 (C4), 153.2 (C6), 136.2 (C11), 134.1 (C14), 132.2 
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(C12), 128.8 (C2), 119.3 (C1), 112.8 (C8), 107.8 (C3), 96.5 (C7), 89.0 (C5), 61.6 (C9), 55.7 
(OCH3), 46.6 (C16), 45.9 (C13), 42.8 (N-CH3), 37.1 (C15), 31.1 (C10). 
  
7,8-Didehydro-6α-hydroxy-17-methyl-4,5-epoxymorphinan (12) 
Yield: 87%. Physical and spectral data were fully in agreement with previously published data 
[1]. 
 
6,7-Didehydro-8β-hydroxy-17-methyl-4,5-epoxymorphinan (13) 
Yield: 85%; white powder; Mp.: 127-128
o
C; calculated for free base C17H19NO22: C, 75.81; 
H, 7.11;  found: C, 75.68; H, 7.20; MS (ESI) m/z 270.2 (M+H
+
), calculated for C17H20NO2
+
: 
270.1; 
1
H-NMR (CDCl3) δ=6.81 (t, 1H, H2, J1-2=7.2, J2-3=7.2), 6.59 (t, 1H, H3, J2-3=7.2),  
6.48 (t, 1H, H1, J1-2=7.2), 5.84 (dd, 1H, H7, J7-6, 7-8α =10.3, <2), 5.56 (dd, 1H, H6, J6-7, 6-5α 
=10.4, 2.0), 5.10 (d, 1H, H5β,  J5β-6=2.7), 4.04 (m, 1H, H8α), 3.17 (dd, 1H, H10α, J10α-10β, 10α-
9=18.6, <2), 2.56-2.20 (m, 7H, H10β, H9, H16α, H16β, NCH3), 1.93 (m, 2H, H15β, H14), 
1.87 (ddd, 1H, H15α, J =5.4, <2, <2). 13C-NMR (CDCl3) δ=157.9, 134.3, 133.0, 131.4, 129.4, 
126.1, 120.0, 109.2, 85.4, 63.5, 59.4, 47.3, 46.0, 45.3, 43.3, 32.9, 21.6. 
 
 
8,14-Didehydro-6α-hydroxy-17-methyl-4,5-epoxymorphinan (14) 
Yield: 91%; white powder; Mp.: 144-145
o
C; calculated for free base C17H19NO2: C, 75.81; H, 
7.11;  found: C, 78.72; H, 7.29; MS (ESI) m/z 270.1 (M+H
+
), calculated for C17H20NO2
+
: 
270.1; 
1
H-NMR (CDCl3) δ=7.02 (t, 1H, H2, J1-2=7.2, J2-3=7.2), 7.06 (t, 2H, H1, H3, J1-2=7.2, 
J2-3=7.2), 5.46 (dd, 1H, H8, J7α-8, 7β-8=3.6, 2.3), 4.67 (d, 1H, H5,  J5β-6β=5.4), 4.19 (dd, 1H, 
H6β, J6β-5β, 7β-5β=5.4, <2), 3.58 (m, 1H, H9), 3.21-2.69 (m, 3H, H10α, H10β, H16α), 2.39-2.15 
(m, 6H, H7α, H7β, H16β, NCH3), 1.91 (ddd, 1H, H15β, J=5.4, >2, >2), 1.81 (ddd, 1H, H15α, 
J =5.4, >2, >2). 
13
C-NMR (CDCl3) δ=159.8, 138.7, 134.5, 131.6, 127.3, 119.2, 113.4, 107.6, 
87.2, 67.1, 57.5, 48.5, 47.1, 43.5, 41.0, 35.4, 20.1.  
 
Acid-catalyzed rearrangement of 3-deoxyoripavine (7) in the presence of alcohols or 
thiols 
A mixture of 7 (200 mg, 0.71 mmol), methanesulfonic acid (1 ml) and alcohol/thiol (200 μl) 
was stirred for 30 min at 90 
o
C. Then the reaction mixture was added dropwise, with stirring 
and external ice-cooling, to a solution of potassium hydrogen carbonate (2 g) in water (10 ml). 
After extraction with dichloromethane (3x15 ml), the combined extracts were washed with 
saturated brine, dried (MgSO4), and concentrated under reducer pressure. The purification of 
10-deoxyapomorphines was performed by means of column chromatography (Kieselgel 40, 
dichloromethane:methanol= 8:2).  
 
The characterizations of the novel morphinans related to the synthesis of cyprodime and new 
aporphines are presented in the supplementary document. 
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Details of the X-ray crystallographic analysis of compound 6  
 
Crystal data 
 
C25H23N5O3 V = 2157.5 (3) Å
3
 
Mr = 441.48 Z = 4 
Orthorhombic, P212121 Mo Kα radiation, λ = 0.71073 Å 
a = 8.226 (1) Å μ = 0.09 mm−1 
b = 11.330 (1) Å T = 293 K 
c = 23.149 (1) Å 0.54 × 0.32 × 0.2 mm 
Data collection 
Enraf Nonius MACH3 
diffractometer 2007 reflections with I > 2σ(I) 
Absorption correction: ψ scan 
 
Selected geometric parameters (Å, º) 
C1—C2  1.394 (7)  C8—C14   1.316 (6) 
C1''—C2''   1.371 (7) C9—N1   1.477 (7) 
C1''—C6''   1.379 (8)  C9—C14   1.515 (6) 
C1''—N2'   1.433 (7) C9—C10   1.550 (8) 
C1'—N5'   1.298 (6) C1'—N2'   1.335 (6)  
C10—C11   1.519 (7) C1'—O1   1.347 (6)  
S3 
 
C2''—C3''   1.375 (9) C11—C12   1.375 (6) 
C2—C3   1.380 (7) C12—C13   1.491 (6) 
C13—C14   1.518 (6) C3''—C4''   1.379 (9)  
C13—C15   1.528 (6) C15—C16   1.514 (7) 
C3—C4   1.367 (7)  C3—O1   1.416 (5)   
C4''—C5''   1.372 (8) C16—N1   1.490 (7) 
C4—O5   1.359 (5)  C4—C12   1.387 (6)  
C18—O3   1.424 (6) C5—C6   1.483 (6)  
C5—O5   1.489 (5)  C5—C13   1.552 (6)  
C19—N1   1.464 (7) C5''—C6''   1.378 (8)  
C6—C7   1.342 (7)  N2'—N3'   1.361 (6)  
C6—O3   1.358 (6)  N3'—N4'   1.292 (7) 
C7—C8   1.458 (7)  N4'—N5'   1.377 (7) 
C11—C1—C2  120.9 (5) C2''—C1''—C6''  121.2 (5)   
C2''—C1''—N2'  119.2 (5) C12—C11—C1  116.3 (4) 
C6''—C1''—N2'  119.5 (5)  C12—C11—C10  118.0 (4) 
N5'—C1'—N2'  112.0 (5) C1—C11—C10  125.3 (4) 
N5'—C1'—O1  127.1 (5) C11—C12—C4  123.3 (4) 
N2'—C1'—O1  120.7 (4)  C11—C12—C13  126.9 (4) 
C1''—C2''—C3''  119.4 (6) C4—C12—C13  109.0 (4) 
C12—C13—C14  103.6 (4) C12—C13—C15  112.6 (4) 
C3—C2—C1   120.5 (5)  C14—C13—C15  110.1 (4) 
C12—C13—C5  101.6 (4) C14—C13—C5  116.4 (4) 
C2''—C3''—C4''  120.1 (6)  C15—C13—C5  111.9 (4) 
C8—C14—C9  128.6 (4) C8—C14—C13  121.2 (4) 
C4—C3—C2   119.4 (4) C9—C14—C13  109.3 (4) 
C4—C3—O1   119.4 (4)  C16—C15—C13  112.1 (4) 
C2—C3—O1   120.7 (5) O5—C4—C3   127.0 (4)   
C3—C4—C12  119.0 (4)  C6—C5—C13  115.4 (4)   
C5''—C6''—C1''  118.9 (5) C7—C6—O3   127.7 (5)   
C7—C6—C5   122.4 (4)  C6—C7—C8  121.7 (5)   
C19—N1—C9  112.5 (4) C19—N1—C16  110.7 (5) 
C14—C8—C7  122.4 (4)  C9—N1—C16  109.9 (4) 
C1'—N2'—N3'  105.9 (4) C1'—N2'—C1''  132.5 (4) 
N1—C9—C14  111.8 (4)  N3'—N2'—C1''  121.5 (4) 
N1—C9—C10  110.1 (4)  N4'—N3'—N2'  107.3 (5) 
C14—C9—C10  111.8 (4)  N3'—N4'—N5'  110.7 (4) 
N1—C9—H9  107.6   C1'—N5'—N4'  104.1 (5) 
C1'—O1—C3  116.5 (4) C6—O3—C18  117.5 (4) 
C11—C10—C9  114.7 (4) C4—O5—C5   106.6 (3) 
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1H and 13C spectra of compound 7 (200 MHz and 50 Mhz, respectively, in CDCl3) 
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1H (200 MHz in CDCl3) and elemental analysis  data of novel morphinans  
Co. Description 
and m.p. 
(oC) 
1H NMR data (ppm, multiplicity and cupling constant in Hz) Elemental analysis 
(%) 
H1 H2 H3 H5 H7 H8 NCH3 OCH3 Calculated Found 
21 white foam 6.41-
6.32 
(m) 
6.87-
6.81 
(m) 
6.41-
6.32 
(m) 
5.01 
(s) 
6.21 
(d, 
6.9) 
6.87-
6.81 
(m) 
2.28 
(s) 
- C: 76.84 
H: 6.81 
N: 4.98 
C: 76.79 
H: 6.91 
N: 5.01 
22 In accordance with ref. 1 
23 In accordance with ref. 1 
24 off-white 
solid, 119-
121 
6.39-
6.31 
(m) 
6.87 
(t, 7.7) 
6.39-
6.31 
(m) 
2.44-
2.31 
(m) 
4.66 
(dd, 
4.9, 
1.2) 
2.17-
1.86 
(m) 
2.31 
(s) 
3.87 
(s) 
3.59 
(s) 
3.24 
(s) 
C: 72.92 
H: 8.26 
N: 4.25 
C: 73.04 
H: 8.33 
N: 4.19 
25 In accordance with ref. 2 
 
1H (200 MHz in CDCl3) and elemental analysis data of novel aporphines 
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Co. Description 
and m.p. 
(oC) 
1H NMR data (ppm, multiplicity and cupling constant in Hz) Elemental analysis 
(%) 
H1 H2 H3 H8 H9 H10 NCH3 
 
S-Alkyl Calculated Found 
15 In accordance with ref. 3 
16 In accordance with ref. 4 
17 In accordance with ref. 4 
18 In accordance with ref. 5 
19 white solid, 
142-145 
7.41 
(d, 
2.1) 
- 7.20-
7.09 
(m) 
6.99 
(dd, 
6.4, 
2.2) 
7.20-
7.09 
(m) 
6.77 
(dd, 
6.4, 
2.2) 
2.31(s) 
 
3.21-2.66 
(m) 
1.27 (t, 
7.2) 
C: 73.27 
H: 6.80 
N: 4.50 
C: 
73.34 
H: 6.68 
N: 4.61 
20 off-white 
solid, 127-
129 
7.31 
(d, 
2.3) 
- 7.14-
7.07 
(m) 
6.90 
(dd, 
6.1, 
2.0)  
7.14-
7.07 
(m) 
6.69 
(dd, 
6.2, 
2.0) 
2.33 
(s) 
 
3.11-2.73 
(m) 
1.34-1.30 
(m) 
0.94 (t, 
6.7) 
C: 73.81 
H: 7.12 
N: 4.30 
C: 
73.61 
H: 7.24 
N: 4.41 
